Related Experiment Video
Updated: May 25, 2026
08:50
Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
Published on: March 26, 2018
Aortic valve replacement in patients with systemic mastocytosis
Kelly M Wanamaker1, George J Magovern, Robert J Moraca
1Department of Cardiovascular and Thoracic Surgery, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA.
Journal of Cardiac Surgery
|January 27, 2012
Summary
Systemic mastocytosis, a hematologic disorder, presents significant perioperative risks due to potential anaphylaxis. This case study details successful management during cardiac surgery, offering insights for similar patients.
Area of Science:
- Hematology
- Anesthesiology
- Cardiovascular Surgery
Background:
- Systemic mastocytosis (SM) is a rare hematologic neoplasm characterized by mast cell accumulation in various organs.
- Patients with SM have heightened risks for anaphylactic reactions due to mast cell mediator release.
- Perioperative management of SM patients undergoing major surgery, especially cardiac procedures, requires careful planning.
Observation:
- A patient with systemic mastocytosis requiring aortic valve replacement was successfully managed.
- The management encompassed preoperative, intraoperative, and postoperative phases.
- Literature review on cardiac surgery in systemic mastocytosis patients was conducted.
Findings:
- Successful anesthetic and surgical management of a systemic mastocytosis patient during aortic valve replacement was achieved.
- Proactive measures mitigated anaphylactic risks associated with stimuli and medications.
- The case highlights the feasibility of complex cardiac surgery in this patient population.
Implications:
- This case demonstrates that cardiac surgery is feasible in patients with systemic mastocytosis with meticulous perioperative care.
- Guidelines for managing perioperative anaphylaxis in systemic mastocytosis patients undergoing cardiac surgery can be refined.
- Further research into optimal anesthetic agents and protocols for systemic mastocytosis patients is warranted.
More Related Videos
Related Concept Videos
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
01:25Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
01:22Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
01:27Mitral Valve Prolapse I: Introduction
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...